Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon 97331, USA.
Nanoscale. 2015 Mar 7;7(9):3888-902. doi: 10.1039/c4nr06050d.
Multifunctional theranostic platforms capable of concurrent near-infrared (NIR) fluorescence imaging and phototherapies are strongly desired for cancer diagnosis and treatment. However, the integration of separate imaging and therapeutic components into nanocarriers results in complex theranostic systems with limited translational potential. A single agent-based theranostic nanoplatform, therefore, was developed for concurrent NIR fluorescence imaging and combinatorial phototherapy with dual photodynamic (PDT) and photothermal (PTT) therapeutic mechanisms. The transformation of a substituted silicon naphthalocyanine (SiNc) into a biocompatible nanoplatform (SiNc-NP) was achieved by SiNc encapsulation into the hydrophobic interior of a generation 5 polypropylenimine dendrimer following surface modification with polyethylene glycol. Encapsulation provides aqueous solubility to SiNc and preserves its NIR fluorescence, PDT and PTT properties. Moreover, an impressive photostability in the dendrimer-encapsulated SiNc has been detected. Under NIR irradiation (785 nm, 1.3 W cm(-2)), SiNc-NP manifested robust heat generation capability (ΔT = 40 °C) and efficiently produced reactive oxygen species essential for PTT and PDT, respectively, without releasing SiNc from the nanopaltform. By varying the laser power density from 0.3 W cm(-2) to 1.3 W cm(-2) the therapeutic mechanism of SiNc-NP could be switched from PDT to combinatorial PDT-PTT treatment. In vitro and in vivo studies confirmed that phototherapy mediated by SiNc can efficiently destroy chemotherapy resistant ovarian cancer cells. Remarkably, solid tumors treated with a single dose of SiNc-NP combined with NIR irradiation were completely eradicated without cancer recurrence. Finally, the efficiency of SiNc-NP as an NIR imaging agent was confirmed by recording the strong fluorescence signal in the tumor, which was not photobleached during the phototherapeutic procedure.
多功能治疗平台,能够同时进行近红外(NIR)荧光成像和光疗,是癌症诊断和治疗的强烈需求。然而,将独立的成像和治疗组件集成到纳米载体中会导致具有有限转化潜力的复杂治疗系统。因此,开发了一种基于单一试剂的治疗纳米平台,用于同时进行 NIR 荧光成像和组合光疗,具有双重光动力(PDT)和光热(PTT)治疗机制。通过将取代的硅萘酞菁(SiNc)封装到第五代聚丙稀亚胺树枝状大分子的疏水性内部,然后用聚乙二醇进行表面修饰,将 SiNc 转化为生物相容性的纳米平台(SiNc-NP)。封装为 SiNc 提供了水溶性,并保留了其近红外荧光、PDT 和 PTT 特性。此外,还检测到树枝状大分子包封的 SiNc 具有令人印象深刻的光稳定性。在 NIR 照射(785nm,1.3W/cm(-2))下,SiNc-NP 表现出强大的产热能力(ΔT=40°C),并分别有效地产生了用于 PTT 和 PDT 的活性氧,而不会将 SiNc 从纳米平台中释放出来。通过将激光功率密度从 0.3W/cm(-2)变化到 1.3W/cm(-2),可以将 SiNc-NP 的治疗机制从 PDT 切换到组合 PDT-PTT 治疗。体外和体内研究证实,SiNc 介导的光疗能够有效地破坏化疗耐药的卵巢癌细胞。值得注意的是,用 SiNc-NP 联合 NIR 照射单次治疗的实体瘤完全被根除,没有癌症复发。最后,通过记录肿瘤中的强荧光信号,证实了 SiNc-NP 作为 NIR 成像剂的效率,在光疗过程中没有光漂白。